Please use this identifier to cite or link to this item:
https://dspace.uzhnu.edu.ua/jspui/handle/lib/2700
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Готько, Євген Степанович | - |
dc.contributor.author | Mary, E. R. | - |
dc.date.accessioned | 2015-06-16T10:30:50Z | - |
dc.date.available | 2015-06-16T10:30:50Z | - |
dc.date.issued | 2008-07 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.uri | https://dspace.uzhnu.edu.ua/jspui/handle/lib/2700 | - |
dc.description.abstract | Background: Patients with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS 2) have limited life expectancies and decreased tolerance for drug-induced toxicities. Current treatment guidelines indicate that PS 2 patients benefit from systemic therapy. Further refinement of treatment in these patients requires reduction of treatment-associated toxicities while maintaining or improving efficacy. Paclitaxel poliglumex (PPX), a macromolecular polymer– drug conjugate of paclitaxel and poly-Lglutamic acid, may enhance the therapeutic index of paclitaxel. | uk |
dc.language.iso | en | uk |
dc.publisher | Journal of Thoracic Oncology | uk |
dc.relation.ispartofseries | Volume 3,;Number 7 | - |
dc.subject | Non-small cell lung cancer | uk |
dc.subject | Paclitaxel poliglumex | uk |
dc.subject | PPX | uk |
dc.subject | CT-2103 | uk |
dc.subject | PS 2 | uk |
dc.subject | Toxicity | uk |
dc.title | Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-NaЇve Advanced Non-small Cell Lung Cancer | uk |
dc.type | Text | uk |
dc.pubType | Стаття | uk |
Appears in Collections: | Наукові публікації кафедри радіології та онкології |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Randomized_Phase_III_Trial_Comparing_Single_Agent.7.pdf | Основна стаття | 216.76 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.